XNYS · Medical Instruments & Supplies
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$224.99-1.50%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
70/100
Strong
Score components
TickerWhale View
Resmed scores 70 out of 100 overall, which we rate strong. Risk is its strongest area and Valuation its weakest.
What helps
- Technical
- Quality & growth
- Valuation
What to watch
Quality & growth
30%81Strong
- Revenue growth 9.8%
- EPS growth 9.7%
Valuation
25%54Moderate
- P/E 21.4
- EV/Sales 5.6
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
#330 by market cap in our coverage · ~10,600 employees · Listed 1995-06-02 · www.resmed.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#14 / 139sector rank by TickerWhale Score
TickerWhale Score 70 vs sector average 55.1 (+14.9)
Revenue growth (industry)Top 43%
Gross margin (industry)Top 20%
Return on equity (industry)Top 7%
P/E (industry)Cheaper than 92%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
67/100Positive vs universe
Ranks 67th of 100 covered names on our technical composite — the composite itself scores 56/100 · 25% of the TickerWhale Score
Classic chart indicators
Strong Sell
0 buy · 4 sell · 4 neutral of 8 votes
TickerWhale rates RMD's technical setup middling — 67th percentile of the covered universe. Classic chart indicators lean sell — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
3 / 9constructive
- vs 200-day-1.0%
- vs 50-day+3.0%
Momentum
Mixed
- RSI (14)50 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength15· weak trend
- MACD (12,26,9)sell(histogram -0.944)
How the classic verdict is reached
Moving averages (9) agree on sell — 3 buy vs 4 sell — and carry one vote between them.
Oscillators (7) vote individually: 0 buy · 3 sell · 4 neutral.
Result — 0 buy vs 4 sell of 8 votes = Strong Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)21.4
- P/S (TTM)5.8
- P/B5.0
- EV/EBITDA—
- EV/Sales5.6
- PEG2.22
Profitability & returns
- Gross margin61.6%
- Net margin26.9%
- ROE23.3%
- Debt/Equity0.10
Growth
- Revenue growth (YoY)9.8%
- EPS growth (YoY)9.7%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $32.7B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RMDCurrentResmed | 70 | 56 | 21.4 | — | 5.0 | 5.6 | $224.99 | -1.50% | +9.8% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.